FDA poised to go digital-first on drug safety labels—with paper as backup
S. 2027 — Prescription Information Modernization Act of 2025 · Filed by Markwayne Mullin (R-OK) · 1 cosponsor · Introduced Jun 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill allows pharmaceutical manufacturers to provide prescribing information to doctors and pharmacists electronically instead of on paper, provided they offer the option to receive or request paper copies at no cost. The FDA must issue regulations within one year to implement this change and ensure healthcare professionals can still get paper copies if they want them, and must hold a public workshop within two years to discuss how to optimize the digital format.
Why we flagged it
The bill's core function is to amend FDA drug-labeling rules to permit digital-only prescribing information delivery, with a regulatory implementation timeline and stakeholder consultation requirement. It is a modernization of existing FDA authority, not a new subsidy or carve-out.
What the text implies
- Shifting the default from paper to digital may reduce prescriber awareness of critical safety information if digital systems are not universally accessible or if prescribers do not actively request paper copies.
- The bill requires manufacturers to provide paper copies 'without additional cost' on request, but does not specify response timelines or penalties for non-compliance, creating potential enforcement gaps.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical manufacturers (reduced printing and distribution costs); digital health information platforms and vendors (potential contracts to host or manage digital pres